Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

11 trials with published results (14%)

Research Maturity

64 completed trials (84% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.3%

4 terminated out of 76 trials

Success Rate

94.1%

+7.6% vs benchmark

Late-Stage Pipeline

17%

13 trials in Phase 3/4

Results Transparency

17%

11 of 64 completed with results

Key Signals

11 with results94% success

Data Visualizations

Phase Distribution

62Total
Not Applicable (9)
P 1 (30)
P 2 (10)
P 3 (5)
P 4 (8)

Trial Status

Completed64
Terminated4
Withdrawn4
Not Yet Recruiting1
Active Not Recruiting1
Recruiting1

Trial Success Rate

94.1%

Benchmark: 86.5%

Based on 64 completed trials

Clinical Trials (76)

Showing 20 of 20 trials
NCT04416945Not ApplicableWithdrawnPrimary

Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic

NCT05052502Not ApplicableCompletedPrimary

Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand

NCT07194668Phase 4Not Yet RecruitingPrimary

R21/MM Dosing, Presentations, and Preservatives

NCT06549257Phase 1Active Not RecruitingPrimary

Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant

NCT04300309Phase 2TerminatedPrimary

Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

NCT06068530Phase 4RecruitingPrimary

Mass Vaccine and Drug Administration, Bangladesh

NCT04093765Not ApplicableCompletedPrimary

Mass Screening and Treatment for Reduction of Falciparum Malaria

NCT04147546Phase 3CompletedPrimary

Additional Screening With Sensitives RDTs and Malaria

NCT04577066Phase 1CompletedPrimary

Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.

NCT03996967Completed

Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia

NCT05192265Phase 2Completed

Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine

NCT00138372CompletedPrimary

Human Immunity to MSP-1 in Western Kenya

NCT01594931Phase 2CompletedPrimary

Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria

NCT00593398CompletedPrimary

Malarial Immunity in Pregnant Cameroonian Women

NCT03783299Phase 4CompletedPrimary

Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic

NCT02614404Phase 1CompletedPrimary

Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria

NCT02450578Phase 1CompletedPrimary

DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria

NCT01872702Not ApplicableCompletedPrimary

Targeted Chemo-elimination (TCE) of Malaria

NCT02867059Phase 1CompletedPrimary

SJ733 Induced Blood Stage Malaria Challenge Study

NCT02543086Phase 1TerminatedPrimary

Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos

Scroll to load more

Research Network

Activity Timeline